Frazier Life Sciences Management, L.P.: MIRUM PHARMACEUTICALS INC (MIRM): Quarterly 13F Position History
As of Q1 2026, Frazier Life Sciences Management, L.P. reported 7,679,684 shares of MIRUM PHARMACEUTICALS INC (MIRM), worth $709.4M and representing 18.3% of its 13F equity book. Quarter-over-quarter share count change: + 884,563 (+13.0%) . The position first appeared in Q1 2022 and has been disclosed across 17 13F-HR filings in Pactolio's tracked window.
- 7,679,684Shares Held (Latest Filing)
- $709.4MReported Market Value (Latest Filing)
- 18.3%Portfolio Weight (% of 13F Equity Book)
- +884,563Quarter-over-Quarter Share Change
- +$172.7MQuarter-over-Quarter Value Change
- 7,679,684Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 17 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 7,679,684 | +884,563 | +13.0% | $709.4M | 18.3% | $92.4 |
| Q4 2025 | 6,795,121 | 0 | — | $536.7M | 14.4% | $79.0 |
| Q3 2025 | 6,795,121 | 0 | — | $498.2M | 14.9% | $73.3 |
| Q2 2025 | 6,795,121 | 0 | — | $345.8M | 13.8% | $50.9 |
| Q1 2025 | 6,795,121 | +224,729 | +3.4% | $306.1M | 14.0% | $45.0 |
| Q4 2024 | 6,570,392 | 0 | — | $271.7M | 11.3% | $41.4 |
| Q3 2024 | 6,570,392 | +75,000 | +1.2% | $256.2M | 10.3% | $39.0 |
| Q2 2024 | 6,495,392 | 0 | — | $222.1M | 10.4% | $34.2 |
| Q1 2024 | 6,495,392 | 0 | — | $163.2M | 6.9% | $25.1 |
| Q4 2023 | 6,495,392 | +25,000 | +0.4% | $191.7M | 10.3% | $29.5 |
| Q3 2023 | 6,470,392 | +2,110,285 | +48.4% | $204.5M | 13.6% | $31.6 |
| Q2 2023 | 4,360,107 | +500,000 | +13.0% | $112.8M | 6.7% | $25.9 |
| Q1 2023 | 3,860,107 | 0 | — | $92.7M | 6.7% | $24.0 |
| Q4 2022 | 3,860,107 | +32,326 | +0.8% | $75.3M | 4.7% | $19.5 |
| Q3 2022 | 3,827,781 | +260,869 | +7.3% | $80.4M | 6.2% | $21.0 |
| Q2 2022 | 3,566,912 | 0 | — | $69.4M | 6.6% | $19.5 |
| Q1 2022 | 3,566,912 | — | — | $78.5M | 6.7% | $22.0 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Frazier Life Sciences Management, L.P. first disclose a MIRM position in 13F-HR filings?
Frazier Life Sciences Management, L.P. first reported MIRUM PHARMACEUTICALS INC (MIRM) on its 13F-HR filing for the period ending 2022-03-31 (Q1 2022). The position has appeared on 17 reported quarters within Pactolio's tracked window.
What was Frazier Life Sciences Management, L.P.'s most recent quarter-over-quarter share-count change in MIRM?
Between Q4 2025 and Q1 2026, Frazier Life Sciences Management, L.P. added 884,563 shares of MIRM (+13.0%), bringing the total reported position to 7,679,684 shares at a market value of $709.4M.
Does the implied price-per-share represent Frazier Life Sciences Management, L.P.'s cost basis in MIRM?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.